Who is sponsoring NCT06048289?

NCT06048289 is sponsored by Zhejiang Cancer Hospital.

What drugs are being tested in NCT06048289?

Interventions in NCT06048289: Blood samples, tumor biopsy specimens will be collected.

What condition does NCT06048289 study?

NCT06048289 studies Biliary Tract Tumor, Cholangiocarcinoma.

Is NCT06048289 still recruiting?

NCT06048289 is currently status unknown. Last updated 25 September 2023.

Last reviewed 2023-09-25 · How we verify

NCT06048289

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy

Status unknown Last updated 25 September 2023

What this trial tests

trial testing Blood samples, tumor biopsy specimens will be collected in Biliary Tract Tumor in 150 participants. Status unknown.

Timeline

14 September 2023

Primary endpoint
31 March 2024

31 March 2025

Quick facts

Lead sponsor	Zhejiang Cancer Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	14 September 2023
Primary completion	31 March 2024
Estimated completion	31 March 2025
Sites	1 location across China

Drugs / interventions tested

Blood samples, tumor biopsy specimens will be collected

Conditions studied

Biliary Tract Tumor — all drugs for Biliary Tract Tumor →
Cholangiocarcinoma — all drugs for Cholangiocarcinoma →

Sponsor

Zhejiang Cancer Hospital

Who can join

18 and older, any sex, with Biliary Tract Tumor or Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, observational study to explore multidimensional biomarkers for predicting the efficacy of immunotherapy In biliary tract tumors

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.
Ni J, Li C, Xu X, Xu Q, et al · · 2025 · cited 2× · PMID 40696434 · DOI 10.1186/s12916-025-04263-z

Verify or expand the search:

Other Zhejiang Cancer Hospital trials

Trials by the same sponsor.

NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06048289 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
Last refreshed: 25 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06048289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing